Hematological Disorders

Surgicel Powder Absorbable Hemostat Available for Bleeding Management

By January 09, 2018

Surgicel Powder Absorbable Hemostat is a powdered adjunctive hemostat used to control disruptive bleeding.

Treating a Common Extraintestinal Manifestation of Inflammatory Bowel Disease

January 05, 2018

Mr. C, a 30-year-old male with Crohn's disease, presented to his clinician with symptoms of fatigue, lethargy, headaches, pallor, hair loss, irritability, and weakness.

Siklos Approved for Pediatric Patients With Sickle Cell Anemia

By December 21, 2017

This is the first FDA approval of hydroxyurea for use in pediatric patients with sickle cell disease.

FDA Lifts Hold on Potential Hemophilia Treatment

By December 15, 2017

Fitusiran, an RNAi therapeutic targeting antithrombin (AT), is designed to lower levels of AT in order to further sufficient thrombin generation to restore hemostasis and prevent bleeding.

Case Study IDs Calciphylaxis Risk Factors, May Aid in Future Prevention

December 14, 2017

The researchers observed significant associations for lupus anticoagulant (48% positive in cases versus 5% in controls), protein C deficiency (50 versus 8%), and combined thrombophilias (62 versus 31%) with calciphylaxis among all patients.

Sickle Cell Disease Treatment Endari Soon to Be Available

By December 11, 2017

Endari is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older.

Iron Deficiency Treatment in a Heart Failure Patient

December 11, 2017

A women with a 30-year history of hypertension, hyperlipidemia and an 8-year history of systolic dysfunction is hospitalized for congestion following a 5-day river cruise.

Gene Therapy Shows Promise in Factor IX Coagulant Activity for Hemophilia B

December 07, 2017

In all participants, vector-derived factor IX coagulant activity was sustained, with a mean steady-state factor IX coagulant activity of 33.7 ± 18.5%.

Possible New Marker of Kidney Disease Identified in Sickle Cell

December 05, 2017

Subsequently, 18 extracellular proteins were focused on, including CP, a protein involved in iron metabolism.

Incidence of Adverse Events Compared Among IV Iron Compounds

By December 04, 2017

It was also found that fewer all-cause ED visits or hospitalizations occurred in non-CKD patients (HR: 0.56; 95% CI: 0.45, 0.70) as well as in NDD-CKD patients (HR: 0.83; 95% CI: 0.71, 0.95) treated with ferumoxytol.

ACC: New Guidance on Managing Bleeding in Patients on Oral Anticoagulants

December 04, 2017

At each step, patient specific factors should be considered.

IV Iron Sucrose Evaluated for Iron Deficiency Anemia in Pediatric IBD

By December 01, 2017

Results of the review also found that 18 adverse events occurred in a total of 13 patients (18.1% of patients; 6.6% of infusions).

Ferric Carboxymaltose Tx Examined in Chronic HF Patients With Iron Deficiency

By December 01, 2017

Results demonstrated that both serum ferritin as well as transferrin saturation were significantly increased after FCM administration.

Frequency of Celiac Disease Testing Examined in Patients with IDA

By November 30, 2017

The subgroup that was most frequently tested was young Caucasian men, with 61% of respondents stating that they would implement serologic testing in this group.

NDA Under Priority Review for Thrombocytopenia in Chronic Liver Disease

By November 28, 2017

A Prescription Drug User Free Act (PDUFA) date has been set for May 21, 2018.

Hemophilic Arthropathy Treatment Gets Orphan Drug Designation

By November 27, 2017

TRM-201 (rofecoxib) is a highly potent COX-2 selective non-steroidal anti-inflammatory drug (NSAID) with a well-established efficacy profile.

Alprolix Labeling Updated With Long-Term Data, Additional Adverse Reaction

By November 27, 2017

Alprolix is a recombinant clotting factor therapy developed using Fc fusion technology to prolong circulation in the body.

Hemlibra Approved to Treat Hemophilia A With Inhibitors

By November 16, 2017

Hemlibra is a bispecific factor IXa- and factor X-directed antibody indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors.

Treating Iron Deficiency Anemia in Patients With Heart Failure

By November 16, 2017

To shed light on the often-challenging management of this common condition, MPR presented the case of a hypothetical patient to a doctor who specializes in advanced heart failure and transplant cardiology.

Effect of Treatment Delay With Tranexamic Acid Examined

November 08, 2017

Overall, 63% of bleeding deaths occurred within 12 hours of onset. There was a peak in deaths from postpartum hemorrhage at 2 to 3 hours after childbirth.

Anticoagulant Linked to Reduced Cancer Incidence

November 08, 2017

"Warfarin use may have broad anticancer potential in a large, population-based cohort of persons older than 50 years," the authors write.

Auryxia Approved for Iron Deficiency Anemia in Patients With CKD

By November 07, 2017

At any point during the 16-week efficacy period, 52.1% (n=61/117) of the Auryxia treated group demonstrated hemoglobin levels of ≥1g/dL compared to 19.1% (n=22/115) of the placebo group.

Lenalidomide Assessed for Hematologic Response in Patients With MDS/MPN-RS-T

November 01, 2017

"While lenalidomide therapy does produce hematological responses in patients with MDS/MPN-RS-T, these are often suboptimal, without significant changes in bone marrow morphology," the authors found.

BLA for Investigational Hemophilia A Treatment Accepted

By October 31, 2017

BAY94-9027 is designed to prolong FVIII activity in the blood while preserving coagulation activity using site-specific technology in which the Polyethylene glycol molecule is consistently attached to the factor VIII protein at a specific site.

AAP Revise Policy Statement on Cord Blood Banking

October 30, 2017

Physicians need to be able to explain concepts of autologous and allogeneic use of cord blood units, as well as benefits and limitations of blood banking and transplantation.

Voluntary Market Withdrawal of Octagam 10% Announced

By October 23, 2017

The Company has decided in conjunction with the FDA to suspend further administration of Octagam 10% from these specific production lots.

Treating Iron Deficiency Anemia in Patients With Inflammatory Bowl Disorder

By October 19, 2017

Despite its frequency, iron deficiency anemia in patients with IBD it is often overlooked in clinical settings.

Blood Transfusions from Ever-Pregnant Donors and Recipient Mortality: What's the Link?

October 18, 2017

Receipt of red blood cell transfusion from ever-pregnant donor tied to increased risk for males.

Thromboembolic Disorder Treatments: Without DVT/PE

October 16, 2017

A comparative medication chart of thromboembolic disorder treatments in patients without DVT/PE.

Anticoagulants Taken With Certain Meds May Up Bleeding Risk

October 05, 2017

And antithrobotic medications linked to higher rate of hematuria-related events in older adults